# NIH grant: Efficacy of a Broadly Neutralizing Monoclonal Antibody Against Mpox in Non-Human Primates (1R01AI199768-01) — retained record

> Retained us-gov-api record from us-gov-api:nih-reporter.

Canonical: https://highsignal.app/data/records/12c92b10ec536d6f

[← sources](https://highsignal.app/data)


source: [us-gov-api](https://highsignal.app/data/us-gov-api) (us-gov-api:nih-reporter)  published 2026-07-17 00:00 ingested 2026-07-20 08:52

[original source ↗](https://reporter.nih.gov/project-details/1R01AI199768-01)

## retained text



```
NIH grant 1R01AI199768-01: Efficacy of a Broadly Neutralizing Monoclonal Antibody Against Mpox in Non-Human Primates
Institute: {'code': 'AI', 'abbreviation': 'NIAID', 'name': 'National Institute of Allergy and Infectious Diseases', 'admin_org_id': '12500003', 'admin_funding_url': ''}. PI: Camila H. Coelho. Award: $781563.
Start: 2026-07-17T00:00:00.
SUMMARY
Mpox (Monkeypox virus, MPXV) has become a global health threat, yet current prevention and
treatment tools remain inadequate. The JYNNEOS vaccine offers limited protection, and
Tecovirimat, the only antiviral tested in humans, has failed in clinical trials. There are currently no
approved monoclonal antibody (mAb) therapies for mpox or any orthopoxvirus. This project
proposes to develop and evaluate EV35-6, a potent mAb targeting A35, a critical MPXV protein
involved in viral dissemination and a promising antibody target not engaged by vaccination. Aim
1 will assess the efficacy and optimal delivery route (intravenous vs. subcutaneous) of EV35-6 in
a rigorously validated non-human primate (NHP) model of mpox that mimics human disease.
Outcomes include clinical protection, reduction in viral load, tissue-level pathology, and
pharmacokinetic profiling. Aim 2 will evaluate whether the presence of EV35-6-like antibodies
correlates with protection in NHPs and determine how broadly EV35-6 binds to A35 orthologs
across multiple orthopoxviruses, including Variola, Vaccinia, Cowpox, and different MPXV clades.
Techniques include competition ELISA, affinity binding assays, and in vitro neutralization. This is
the first study to test a monoclonal antibody for mpox in NHPs. It will generate critical data for the
clinical development of EV35-6 and set a foundation for rational, epitope-driven antibody
therapies for mpox and other orthopoxvirus threats.
```



document fetched 2026-07-26 08:23